MerLion Pharmaceuticals GmbH

  • Healthcare
  • Bioscience
  • Medical Care & Services
Robert-Rössle-Str. 10
Berlin, Non-US State 13125
+493094894050

About Us

MerLion Pharmaceuticals is a biopharma company focusing on the research, development and commercialization of drugs for the treatment of serious bacterial infections.
MerLion is working primarily on read more
  • About

    MerLion Pharmaceuticals is a biopharma company focusing on the research, development and commercialization of drugs for the treatment of serious bacterial infections.
    MerLion is working primarily on developing Finafloxacin, which has been designated a Qualified Infectious Disease Product (QIDP), as a therapeutic option for the treatment of bacterial infections in the human health sector:
    Xtoro:
    Xtoro is a US FDA- and Health Canada-approved drug containing Finafloxacin for the treatment of ear infections.
    Biodefense:
    Finafloxacin is being developed as a medical countermeasure against biothreat agents.
    cUTI:
    Finafloxacin is an important candidate for treatment of cUTI (complicated Urinary Tract Infections) and other infections such as hospital acquired pneumonia, skin infections and intra-abdominal infections that are treated in the hospital.

  • Whom to Contact

    • Ines Nemack
    //WEB000352460